{
    "organizations": [],
    "uuid": "ede196e9e20a045f6037851d4a2e18f667e7adf0",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-says-key-lung/brief-bristol-myers-squibb-says-key-lung-cancer-trial-meets-main-goal-idUSFWN1PV0V1",
    "ord_in_thread": 0,
    "title": "BRIEF-Bristol-Myers Squibb Says Key Lung Cancer Trial Meets Main Goal",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 5, 2018 / 12:22 PM / in 18 minutes BRIEF-Bristol-Myers Squibb Says Key Lung Cancer Trial Meets Main Goal Reuters Staff 1 Min Read \nFeb 5 (Reuters) - Bristol-Myers Squibb Co: \n* PIVOTAL PHASE 3 CHECKMATE -227 STUDY DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL (PFS) WITH THE OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH HIGH TUMOR MUTATION BURDEN (TMB) \n* BRISTOL-MYERS - PHASE 3 CHECKMATE -227 STUDY MET CO-PRIMARY ENDPOINT OF PFS WITH OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY \n* BRISTOL-MYERS - TRIAL WILL CONTINUE AS PLANNED TO ASSESS OPDIVO-YERVOY COMBO FOR OTHER CO-PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH PD-L1 TUMORS Source text for Eikon: Further company coverage:",
    "published": "2018-02-05T14:19:00.000+02:00",
    "crawled": "2018-02-05T14:41:41.029+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "squibb",
        "say",
        "key",
        "lung",
        "cancer",
        "trial",
        "meet",
        "main",
        "goal",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "squibb",
        "co",
        "pivotal",
        "phase",
        "checkmate",
        "study",
        "demonstrates",
        "superior",
        "survival",
        "pfs",
        "opdivo",
        "plus",
        "yervoy",
        "combination",
        "versus",
        "chemotherapy",
        "cell",
        "lung",
        "cancer",
        "nsclc",
        "patient",
        "high",
        "tumor",
        "mutation",
        "burden",
        "tmb",
        "phase",
        "checkmate",
        "study",
        "met",
        "endpoint",
        "pfs",
        "opdivo",
        "plus",
        "yervoy",
        "combination",
        "versus",
        "chemotherapy",
        "trial",
        "continue",
        "planned",
        "assess",
        "combo",
        "endpoint",
        "overall",
        "survival",
        "patient",
        "tumor",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}